Nalanda India Equity Fund Limited has reported an acquisition of shares in Jyothy Laboratories Limited. The fund now holds 24,838,446 shares, representing 6.76% of the total voting capital. This disclosure, made as per SEBI regulations, details the transaction which occurred on September 2, 2026, with settlement on September 3, 2026. The acquisition has resulted in the total diluted share/voting capital of Jyothy Laboratories Limited after this transaction being 0, suggesting a potential reclassification or sale of other holdings by the fund.
| Announcement Date | September 3, 2026 |
| Acquiring Entity | Nalanda India Equity Fund Limited |
| Target Company | Jyothy Laboratories Limited |
| Nature of Transaction | Acquisition of Shares |
Shareholding Details
Nalanda India Equity Fund Limited has disclosed its acquisition of shares in Jyothy Laboratories Limited. As per the ‘Annexure-2’ format for disclosures under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, the fund’s holding before the purchase was 24,838,446 shares, which constituted 6.76% of the total share capital.
Following the transaction, details of the buy indicate that 3,102,384 shares were sold, resulting in a holding of 0.85% after the transaction. However, the statement for ‘After the disposal holding of’ shows shares carrying voting rights at 27,940,830, representing 7.61%. This implies a net acquisition or a complex series of transactions.
Transaction Timeline
The mode of sale is described as Exchange. The shares were traded on September 2, 2026, with the settlement date recorded as September 3, 2026.
The equity share capital and total voting capital of Jyothy Laboratories Limited before the said purchase was 367,214,511. The total diluted share/voting capital of the TC after the said purchase is stated as 0.
The disclosure was signed by Arshad Goodur, Director, on behalf of Nalanda India Equity Fund Limited.
Source: BSE
